Research map: Antibody Drug Conjugates in Urothelial Carcinoma: Current Evidence and Practice Considerations

Back to the article

Papers in this map

  1. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial · Thomas B. Powles · 2017 · 1444 citations · Cited by this paper
  2. Acupuncture in Cancer Care: Evidence, Safety, and Implementation in Oncology Practice · 2026 · Related
  3. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma · Thomas B. Powles · 2021 · 1236 citations · Cited by this paper
  4. Survival Outcomes in Breast Cancer Patients With Use of Vaginal Estrogen Therapy: A SEER Analysis · 2026 · Related
  5. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 · Yusuke Ogitani · 2016 · 1193 citations · Cited by this paper
  6. Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid Tumors · 2026 · Related
  7. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  8. Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021 · 2026 · Related
  9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  10. When Systems Fail the Vulnerable: Cancer Care for Patients With Mental Illness · 2026 · Related
  11. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma · Thomas B. Powles · 2017 · 874 citations · Cited by this paper
  12. Implementing Systems-Based Interventions to Improve the Care of Cancer Survivors: Small Steps, Large Challenges · 2026 · Related
  13. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy · Jonathan E. Rosenberg · 2019 · 649 citations · Cited by this paper
  14. Availability and Use of Social Determinants of Health Data in Alliance Gastrointestinal Cancer Clinical Trials · 2026 · Related
  15. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study · Andrea Borghese Apolo · 2017 · 588 citations · Cited by this paper
  16. Patient Engagement With an Electronic Patient-Reported Outcomes Tool Evaluating Hospital Discharge Readiness After Cancer Surgery · 2026 · Related
  17. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study · Elizabeth R. Plimack · 2017 · 337 citations · Cited by this paper
  18. Participation Is Not Reform: Why 340B Discounts Should Follow the Patient · 2026 · Related
  19. Upregulation of Trop-2 quantitatively stimulates human cancer growth · Marco Trerotola · 2012 · 334 citations · Cited by this paper
  20. Dose Optimization and the Implementation of Project Optimus · 2026 · Related
  21. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells · Daisuke Okajima · 2021 · 327 citations · Cited by this paper
  22. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer · Christopher J. Hoimes · 2022 · 282 citations · Cited by this paper
  23. Optimizing the safety of antibody–drug conjugates for patients with solid tumours · Paolo Tarantino · 2023 · 258 citations · Cited by this paper
  24. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development · Raffaele Colombo · 2024 · 229 citations · Cited by this paper
  25. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients · Marick E Lae · 2009 · 228 citations · Cited by this paper
  26. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes · Yohann Loriot · 2024 · 95 citations · Cited by this paper
  27. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer · Xinan Sheng · 2025 · 95 citations · Cited by this paper
  28. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial · Thomas B. Powles · 2025 · 93 citations · Cited by this paper
  29. Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303 · Matthew D. Galsky · 2021 · 73 citations · Cited by this paper
  30. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study · Li Qun Zhou · 2024 · 63 citations · Cited by this paper
  31. KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). · Christopher J. Hoimes · 2021 · 47 citations · Cited by this paper
  32. LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study · Christof Vulsteke · 2025 · 43 citations · Cited by this paper
  33. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. · Funda Meric‐Bernstam · 2025 · 16 citations · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper

Source: OpenAlex (CC0)